Clinical Trial Update: CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer [Phase 1]

View source ↗

Summary

This clinical trial update describes CSB-321, an immunotherapy, in Phase 1 testing for metastatic cancer and unresectable solid tumors, which is not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Unresectable Solid Tumor

Drugs mentioned

• CSB-321

Snippet

Sponsor: Cytosite Biopharma Inc. | Conditions: Metastatic Cancer, Unresectable Solid Tumor | Phase 1 | Status: NOT_YET_RECRUITING